Psychoneuroendocrinology
Volume 32, Issue 7 , Pages 777-784 , August 2007

Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats

  • Mari Murashita

      Affiliations

    • Department of Psychiatry, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81117065160; fax: +81117065081.
    • ,
  • Ichiro Kusumi

      Affiliations

    • Department of Psychiatry, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638, Japan
    • ,
  • Hiroshi Hosoda

      Affiliations

    • Department of Biochemistry, National Cardiovascular Center Research Institute, Fujishiridai 5-7-1, Suita-city, Osaka 565-8565, Japan
    • ,
  • Kenji Kangawa

      Affiliations

    • Department of Biochemistry, National Cardiovascular Center Research Institute, Fujishiridai 5-7-1, Suita-city, Osaka 565-8565, Japan
    • ,
  • Tsukasa Koyama

      Affiliations

    • Department of Psychiatry, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638, Japan

Received 20 October 2006 ,Revised 26 April 2007 ,Accepted 7 May 2007.

References 

  1. Allison DB, Montore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 1999;156:1686–1696
  2. American Diabetes Association, American Psychiatry Association, American Association of Clinical Endocrinologists and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601
  3. Ardizzone TD, Bradley RJ, Freeman AM, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res. 2001;923:82–90
  4. Ariyasu H, Tanaka K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J. Clin. Endocrinol. Metab. 2001;86:4753–4758
  5. Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol. Psychiatry. 1998;3:76–80
  6. Burcelin R, Uldry M, Foretz M, Perrin C, Dacosta A, Nenniger-Tosato M, et al. Impaired glucose homeostasis in mice lacking of α1b-adrenergic receptor subtype. J. Biol. Chem. 2004;279:1108–1115
  7. Chaouloff F, Laude D, Baudrie DV. Effects of the 5-HT1C/2 receptor agonists DOI and α-methyl-5-HT on plasma glucose and insulin levels in the rat. Eur. J. Pharmacol. 1990;177:107–110
  8. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BS, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50:1714–1719
  9. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. 2002;346:1623–1630
  10. Date Y, Murakami N, Toshinai K, Matsukura S, Nijima A, Matsuo H, et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology. 2002;123:1120–1128
  11. Dunning BE, Taborsky GJ. Neural control of islet function by norepinephrine and sympathetic neuropeptides. Adv. Exp. Med. Biol. 1991;291:107–127
  12. Dwyer DS, Pinkofsky HB, Liu Y, Bradley RJ. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1999;23:69–80
  13. Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol. Biochem. Behav. 2003;75:255–260
  14. Elman I, Goldstein DS, Eisenhofer G, Foklio J, Malhotra AK, Adler CM, et al. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology. 1999;20:29–43
  15. Flechtner-Mors M, Jenkinson CP, Alt A, Biesalski HK, Adler G, Ditschuneit HH. Sympathetic regulation of glucose uptake by the α-adrenoreceptor in human obesity. Obesity Res. 2004;12:612–620
  16. Haring C, Meise U, Humpel C. Dose related plasma levels of clozapine: influence of smoking behavior, sex and age. Psychopharmacology. 1989;99:S38–S40
  17. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am. J. Psychiatry. 2000;157:975–981
  18. Hosoda H, Kangawa K. Ghrelin regulation of autonomic nerve system. Folia Endocrinol. Japonia. 2005;81:P192;(Abstract)
  19. Hosoda H, Kojima M, Matsuo H, Kangawa K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem. Biophys. Res. Commun. 2000;279:909–913
  20. Hosoda H, Doi K, Nagaya N, Okimura H, Nakagawa E, Enomoto M, et al. Optimum collection and storage conditions for ghrelin measurements: octanoyl modification of ghrelin is rapidly hydrolyzed to desacyl ghrelin in blood samples. Clin. Chem. 2004;50:1077–1080
  21. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–660
  22. Krediet RT, Dunning AJ. Baroreflex sensitivity in hypertension during beta-adrenergic blockade. Br. Heart J. 1979;41:106–110
  23. Lean MEJ, Pajonk FG. Patients on atypical antipsychotic drugs. Diabetes Care. 2003;26:1596–1597
  24. Mark AL, Rahmouni K, Correia M, Haynes WG. A leptin–sympathetic–leptin feedback loop: potential implications for regulation of arterial pressure and body fat. Acta. Physiol. Scand. 2003;177:345–349
  25. Meltzer HY. Monitoring clozapine. Hosp. Community Psychiatry. 1990;41:1356–1357
  26. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonine 2 pKi values. J. Pharmacol. Exp. Ther. 1989;251:238–246
  27. Murashita M, Kusumi I, Inoue T, Takahashi Y, Hosoda H, Kangawa K, et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology. 2005;30:106–110
  28. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409:194–198
  29. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry. 2002;59:337–345
  30. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 1996;124:57–73
  31. Schwartz MW, Woods SC, Porte D, Seeley RJ, Bakin DG. Central nervous system control of food intake. Nature. 2000;404:661–671
  32. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 2001;50:227–232
  33. Sivitz WI, Fink BD, Morgan DA, Fox JM, Donohue PA, Haynes WG. Sympathetic inhibition, leptin, and uncoupling protein subtype expression in normal fasting rats. Am. J. Physiol. 1999;277:E668–E677
  34. Spivak B, Roitman S, Vered Y, Master R, Graff E, Talmon Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin. Neuropharmacol. 1998;21:245–250
  35. Sugimoto Y, Yamada J. Effects of 5-HT2A receptor antagonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) on plasma glucose and glucagon levels of rats. Biol. Pharm. Bull. 2000;23:1521–1523
  36. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature. 1995;374:542–546
  37. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry. 1999;60:358–363
  38. Wren AM, Small CJ, Ward HL. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology. 2000;141:4325–4328
  39. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Choen MA, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001;50:2540–2547
  40. Yamaguchi N. Sympathoadrenal system in neuroendocrine control of glucose : mechanism involved in the liver, pancreas, and adrenal gland under hemorrhagic and hypoglycemia stress. Can. J. Physiol. Pharmacol. 1992;70:167–206
  41. Young CR, Bowers MB, Mazure CM. Management of adverse effects of clozapine. Schizophr. Bull. 1988;24:381–390

PII: S0306-4530(07)00114-X

doi: 10.1016/j.psyneuen.2007.05.007

Psychoneuroendocrinology
Volume 32, Issue 7 , Pages 777-784 , August 2007

Article Tools

* Image Usage & Resolution